Introduction
Atrial fibrillation (AF) is a common, persistent cardiac arrhythmia and is associated with remarkably increased rates of hospitalization, morbidity, and mortality. 1, 2 Despite clinical and fundamental research efforts over the past few decades, the mechanisms underlying AF remain unclear. AF is complex arrhythmia originating from an abnormal atrial substrate and has various predisposing factors, such as heart failure (HF), diabetes, ischemic heart disease, aging, hypertension, obesity, obstructive sleep apnea, genetic factors, and cardiorespiratory fitness. 3, 4 The abnormal atrial substrate for AF involves electrical, structural, and ionic changes, and this phenomenon is termed as "atrial remodeling".
Oxidative stress and inflammation play important roles in the promotion of atrial remodeling, leading to atrial ectopy, atrial interstitial fibrosis, and increased risk of stroke. 3, 5 A reasonable amount of experimental and clinical evidence indicates that atrial fibrosis plays an important role in AF. 6, 7 Atrial fibrosis occurs when fibroblasts differentiate to myofibroblasts in the myocardium, resulting in collagen deposition. TGF-β1 plays a vital role in collagen synthesis and is expressed at high levels in the fibrotic cardiac tissue. Progressive accumulation of the fibrous tissue in the myocardium is one of the major aspects of cardiac structural remodeling. The formation and redistribution of the fibrous tissue modulate myocardial geometry to adapt to new conditions of pathophysiological functioning. This adaptation process involves the extracellular matrix (ECM), which contains large amounts of fibers and collagen. The normal cardiac ECM plays an important role in maintaining homeostasis between matrix protein synthesis and degradation. However, excessive ECM production commonly results in abnormalities in cardiac contraction and relaxation. 8 Drugs that prevent myocardial fibrosis and improve heart function might be useful for AF. In recent years, accumulating experimental evidence has suggested that the inhibition of atrial fibrosis using drugs, such as eplerenone, 9 aliskiren, 10 and taurine, 11 effectively inhibits AF susceptibility in patients and animal models.
The traditional Chinese medicine, Shensong Yangxin (SSYX) capsule, has been widely used to treat cardiac arrhythmia. It consists of 12 ingredients (Table 1) , and its use has been approved by the State Food and Drug Administration of China in 2003 (File No Z20030058). It is used in the treatment of atrial premature complexes and ventricular premature complexes in China. 12, 13 Clinical studies have demonstrated that SSYX capsule can effectively reduce paroxysmal AF.
14 Furthermore, previous studies by patch clamp have suggested that SSXY capsule can inhibit multiple ion channels related to AF. 15, 16 Preliminary studies have suggested that SSYX capsule could inhibit ventricular fibrosis and improve cardiac function in diabetic rats. 17 However, the effect of SSYX on atrial fibrosis remains unclear. The antifibrosis effect of SSYX in the atria may be a potential mechanism for treating AF. The present study aimed to determine the effect of SSYX on atrial fibrosis in myocardial infarction (MI)-induced HF rats and to explore the underlying molecular mechanisms. Table 1 . The quality of SSYX capsule was confirmed by ultrahigh performance liquid chromatography combined with quadrupole time-of-flight mass spectrometry, as previously described. 18 
Materials and methods shensong Yangxin

animal model
Male Sprague Dawley rats (weight, 250-280 g) were obtained from the Animal Center of Southern Medical University. All experimental procedures were performed in strict accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (publication number 85-23, revised 1996) , and all studies were approved by the Animal Care Committee of Guangdong Provincial Hospital of Chinese Medicine (No 2016044). The rats underwent MI establishment surgery or sham surgery. MI was established by ligating the coronary artery, as previously described. 19 Briefly, rats were anesthetized, intubated, and then ventilated (Harvard 
echocardiography
Serial echocardiography was performed using a highresolution echocardiography system (Vevo 2100; VisualSonics Inc., Toronto, ON, Canada) at 1 and 5 weeks after MI, respectively. All the 45 rats were anesthetized with isoflurane. Transthoracic echocardiography was performed with a 21 MHz phased array probe to measure EF and fractional shortening using M-mode recordings obtained at the level of the papillary muscles. Each echocardiographic variable was determined in at least four separate left ventricular images of the same heart.
Programmed electrical stimulation and induction of aF
AF was defined as irregular, atrial arrhythmia and rapid atrial activation with varying electrographic morphologies lasting for $2 seconds. 20 After the induction of anesthesia, the tracheal cannula was intubated via the mouth and mechanical ventilation was initiated with a small animal ventilator (Harvard Apparatus Co.). For atrial stimulation, a 4-French quadripolar catheter was advanced through the esophagus and placed at the site with the lowest threshold for atrial capture. The inducibility of atrial arrhythmia was tested using the automated stimulator software by applying 35-second bursts. Each burst had a cycle length of 20 ms and pulse width of 5 ms. AF was considered in case of rapid, irregular atrial rhythm lasting for at least 2 seconds following burst pacing. AF was considered inducible if $1 burst in two series of bursts evoked an AF episode in rats. AF inducibility and duration were recorded and analyzed.
Multielectrode array (MEA) measurements
MEA technology was utilized in vitro 4 weeks after SSYX capsule administration. After the induction of anesthesia, the heart was immediately removed, and the left atrium was excised from the isolated heart and immersed in modified Tyrode's solution (composition in mmol/L: NaCl, 130; NaHCO 3 , 20; NaH 2 PO 4 , 1.2; MgCl 2 , 1; KCl, 4.0; glucose, 5.6; CaCl 2 , 1.8; 2,3-butanedione monoxime, 15; pH 7.4). An MEA dish (Multi Channel Systems, Reutlingen, Germany) containing 120 tipped platinum electrodes with an electrode height between 25 and 35 µm and interelectrode distance of 100 µm was used. The electrode arrays were mounted onto a printed circuit board and were then fitted into the MEA 2100 System interface (Multi Channel Systems). The atrium was positioned at the center of the MEA dish, kept in contact with the 120 electrodes using a slice holder, and continuously superfused with oxygenated modified Tyrode's solution at 37°C. Electrical stimulation (bipolar pulses, 1-7 V; duration, 1,000 µs) was applied via one of the MEA microelectrodes. Data were sampled at 10 kHz per channel with simultaneous data acquisition using Cardio2D+ software (Multi Channel Systems). Five fields were recorded in each atrium. All data were analyzed to generate activation maps and measure the conduction velocity (CV).
Masson's trichrome staining
Atrial tissue samples were fixed in 4% paraformaldehyde for 24 hours. The left atrium was then cut into two half longitudinal sections. After standard paraffin embedding, Masson's trichrome staining was performed. The total left atrial fibrosis area (%) was calculated using cellSens Viewer software (Olympus Imaging Corp., Tokyo, Japan) to evaluate left atrial fibrosis in each group.
Western blot analysis
Total protein was obtained from the left atrium, subjected to standard procedures, and its concentration was determined using the bicinchoninic acid protein assay kit (Thermo Fisher Scientific, Waltham, MA, USA). Protein samples were separated using 10% SDS-PAGE and transferred onto a polyvinylidene difluoride membrane. The membrane was blocked with 5% skimmed milk for 1 hour at room temperature and was incubated with primary antibodies overnight at 4°C. The diluted concentrations of the primary antibodies 
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Ma et al (Abcam, Cambridge, UK; Santa Cruz Biotechnology; or Cell Signaling Technology) were as follows: collagen I, 1:500; collagen III, 1:500; α-smooth muscle actin (α-SMA), 1:1,000; TGF-β1, 1:1,000; mothers against decapentaplegic homolog 3 (Smad3), 1:500; matrix metalloproteinase 9 (MMP-9), 1:500; tissue inhibitor of metalloproteinase 1 (TIMP-1), 1:500; and GAPDH, 1:1,000. The secondary antibodies (Cell Signaling Technology) were horseradish peroxidase-labeled antibodies diluted at 1:3,000. The membrane was incubated with secondary antibodies for 1 hour at 25°C. Protein bands were visualized using Enhanced Chemiluminescence Plus (EMD Millipore, Billerica, MA, USA). GAPDH was used as the internal control. The final results were expressed as fold changes by normalizing the data to control values.
Data analysis and statistics
Data are expressed as the mean±SD, except AF duration, which is expressed as the median and IQR (25%-75%). AF inducibility comparisons between the control and SSYX groups were performed using the Fisher's exact test. Comparisons between groups were performed with ANOVA followed by the Bonferroni post-test, and the least significant difference method was used for post hoc multiple comparisons. All statistical analyses were performed using SPSS version 13.0 software (SPSS Inc., Chicago, IL, USA). A P-value ,0.05 was considered statistically significant. Figure 1A shows a representative electrocardiogram of atrial burst stimulation-induced AF. Before the burst, the rat was in sinus rhythm (Figure 1Aa ). After termination of the burst, the rat was in irregular atrial rhythm with irregular ventricular response (Figure 1Ab ). The AF episode terminated spontaneously within a few seconds and sinus rhythm resumed (Figure 1Ac) . In contrast, a noninduced rat continued to show sinus rhythm after the burst (Figure 1Ad ). The rate of AF inducibility was markedly higher in the MI group (73.3%) than in the sham group (6.67%) and markedly lower in the SSYX group (33.3%) than in the MI group ( Figure 1B) . Furthermore, the mean AF episode duration was significantly higher in the MI group (251-1,060 seconds) than in the sham group (11.7-47.8 seconds) and significantly lower in the SSYX group (52.5-303.8 seconds) than in the MI group (P,0.05; Figure 1C ).
Results
SSYX attenuated the inducibility and duration of aF
ssYX improved cardiac function and atrial conduction function after Mi
Cardiac function was evaluated with echocardiography. Echocardiography was performed 4 weeks after SSYX administration. Representative M-mode echocardiograms for the groups are presented in Figure 2A . EF% and fraction shortening (%) were significantly lower in the MI group (37.8%±3.1% and 19.2%±1.7%, respectively) than in the sham group (76.5%±7.1% and 41.2%±4.3%, respectively) and higher in the SSYX group (46.4%±6.2% and 24.5%±3.8%, respectively) than in the MI group (P,0.05; Figure 2B and C).
Left atrial surface conduction activation maps ( Figure 3A ) and CV maps ( Figure 3B ) demonstrated crowding of isochrones and a slower CV in the MI group (13.5±3.7 cm/s) than that in the sham group (35.1±2.5 cm/s, P,0.01), in addition to heterogeneous conduction. On the other hand, left atrial CV was higher (P,0.01; Figure 3C ) and homogeneity was better in the SSYX group than in the MI group.
SSYX inhibited left atrial interstitial fibrosis
Collagen production and deposition were evaluated using Masson's trichrome staining and Western blot analysis. Fibrosis-positive areas in the left atrium were more common in the MI group than in the sham group ( Figure 4A ) and less common in the SSYX group than in the MI group (P,0.05; Figure 4B ). Type I and III collagen expressions were examined using Western blot analysis and were found to be significantly higher in the MI group than in the sham group and markedly lower in the SSYX group than in the MI group (P,0.05; Figure 4C and D).
SSYX inhibited the differentiation of cardiac fibroblasts to myofibroblasts
α-SMA is a marker for the differentiation of fibroblasts to myofibroblasts. Therefore, we used Western blot analysis to assess the role of SSYX in the differentiation of fibroblasts to myofibroblasts. α-SMA expression was significantly higher in the MI group than in the sham group. Interestingly, α-SMA expression was significantly lower in the SSYX group than in the MI group (P,0.05; Figure 5A ). The TGF-β1 signaling pathway has been reported to be important for fibrosis progression in various organs. In the present study, we explored whether SSYX could attenuate fibrosis through the TGF-β1 signaling pathway. Western blot analysis indicated that TGF-β1 expression was significantly 
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Ma et al higher in the MI group than in the sham group and lower in the SSYX group than in the MI group (P,0.05; Figure 5B ). However, Smad3 expression did not differ among the sham, MI, and SSYX groups (P.0.05; Figure 5C ).
ssYX downregulated MMP-9 and TiMP-1 expressions
MMPs are proteolytic enzymes involved in the degradation of collagen and ECM components.
10-14 TIMP maintains the homeostatic balance of myocardial ECM by inhibiting activated matrix MMPs. MMP and TIMP expressions are consistently upregulated in myocardial fibrosis; hence, these proteins can be used as markers for fibrosis. We, therefore, investigated the effect of SSYX on MMP-9 and TIMP-1 expressions. Western blot analysis showed that MMP-9 and TIMP-1 expressions were significantly higher in the MI group than in the sham group and significantly lower in the SSYX group than in the MI group (Figure 5D and E; P,0.05). 
Discussion
This study investigated the effect of SSYX on chronic MIinduced atrial fibrosis and AF inducibility. The main findings of this study are as follows: 1) SSYX treatment resulted in a significant reduction in the AF inducibility rate and shortening of AF duration in rats with chronic MI; 2) SSYX treatment effectively alleviated conduction heterogeneity and improved left atrial conduction function; 3) SSYX treatment inhibited left atrial fibrosis; and 4) SSYX treatment inhibited the differentiation of cardiac fibroblasts to myofibroblasts by affecting the TGF-β1 pathway.
HF and AF commonly coexist, and adversely affect mortality and increase the economic burden. 21 HF in patients and animal models has been shown to remodel the atrial structure, electrophysiology, and intracellular Ca 2+ handling, which eventually increases susceptibility to AF. [22] [23] [24] [25] HF is one of the important causes of AF;
26,27 therefore, we chose the MIinduced HF disease model in the present study. AF requires both a substrate and a trigger for initiation. The primary substrate is atrial remodeling (fibrosis, chamber enlargement, and atrial hypertrophy, leading to increased susceptibility to AF), whereas the primary triggers are ischemia, inflammation, and catecholamine stress. [28] [29] [30] Atrial fibrosis is an important component of the arrhythmogenic substrate in patients with AF. It has been shown to increase electrical conduction disturbance and promote AF in different disease models. 20, 31 Ginsenoside Rb1 and Rg1 are the main active ingredients of ginseng, which have potential effects of attenuating liver fibrosis through the downregulation of hepatic TIMP-1 32 and inhibiting cardiac fibrosis through phosphor-Akt activation 
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Ma et al and P38 MAPK inhibition. 33 The compound 7-O-galloyl-dsedoheptulose isolated from Corni has been shown to have antifibrotic potential in diabetic mice. 34, 35 In addition, active compounds from Salvia have been shown to inhibit myocardial fibrosis 36, 37 and hepatic fibrosis through the TGF-β1 pathway. 38 SSYX contains a variety of antifibrotic components. Therefore, SSYX may have the potential to inhibit left atrial fibrosis and indirectly inhibit AF susceptibility in rats and humans with post-MI HF.
In this study, chronic MI-induced HF in rats resulted in significant left atrial fibrosis, left atrial conduction heterogeneity, and left ventricular dysfunction, and these findings are similar to the results reported in a previous study. 39 However, SSYX treatment significantly attenuated atrial fibrosis, improved cardiac function, and decreased the AF inducibility rate.
Regional heterogeneity with regard to left atrial CV is an important substrate for the development of AF. 40 In the left atrium of patients undergoing radiofrequency ablation for AF, optical mapping revealed conduction abnormalities with different longitudinal CV values in different regions. 41 In this study, conduction heterogeneity was noted in the left atrium of rats with MI-induced HF, and the mean CV was lower in these rats than in sham-operated rats. Lee et al found that pirfenidone treatment in canines with HF significantly reduced not only conduction heterogeneity but also AF vulnerability to levels similar to those in controls. 42 We also found that the mean CV significantly improved and AF vulnerability reduced with SSYX treatment; however, AF vulnerability in SSYX-treated rats was significantly higher than that in sham-operated rats. Li et al reported that AF vulnerability reduced with enalapril treatment in the canine model of HF, but was significantly higher than that in controls. 43 Our result is consistent with this previous finding.
TGF-β1 is a potent stimulator of collagen production through the Smad pathway, 44 which is a critical pathway involved in the promotion of fibrosis. 45 Kupfahl et al noted that angiotensin II may upregulate TGF-β1 expression in human atrial tissue, and that TGF-β1 signaling may increase collagen production. 46 Overexpression of cardiac TGF-β1 has been shown to increase atrial fibrosis, conduction heterogeneity, and AF inducibility. 20 Furthermore, SSYX decreases TGF-β1 expression in different disease models, including rats with diabetes and rabbits with chronic MI, 17, 39 which is consistent with our findings. In the present study, TGF-β1 expression increased after MI, and SSYX treatment ameliorated this effect. Atrial ECM homeostasis is regulated by a balance between MMPs and TIMPs. It has been reported that elevated tissue and plasma TIMP-1 levels are correlated with myocardial fibrosis, and that TIMP-1 has been used as a biomarker for fibrosis in humans and animal models. 47, 48 Takawale et al 49 reported that loss of TIMP-1 ameliorated myocardial fibrosis through a reduction in collagen expression, and that absence of TIMP-1 improved cardiac function in TIMP-1-deficient mice. These findings are consistent with our results. In the present study, TIMP-1 expression remarkably increased in the chronic MI rat model and significantly reduced after SSYX treatment. In addition, SSYX treatment inhibited myocardial fibrosis by reducing collagen type I and III and α-SMA expressions. The present results suggest that SSYX attenuates AF vulnerability by attenuating atrial fibrosis, inhibiting the differentiation of fibroblasts to myofibroblasts, and improving atrial conduction.
Conclusion
AF has traditionally been treated with antiarrhythmic drugs (ion-channel blockers), which have proarrhythmic risks. Traditional Chinese medicines have been used owing to their prominent advantages, including stable curative effects and low toxicity. In the present study, SSYX reduced AF inducibility after MI by improving left atrial conduction function via inhibition of left atrial fibrosis. It also prevented the development of MI-induced vulnerable substrate for AF.
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